ARV-6723
Undisclosed Oncology
Phase 1Active
Key Facts
About Arvinas
Arvinas is a leader in the field of targeted protein degradation, developing novel therapeutics through its proprietary PROTAC® platform. The company has achieved significant clinical validation, with its lead oncology asset, vepdegestrant, demonstrating efficacy in pivotal trials for breast cancer, and its neuroscience candidate, ARV-102, showing compelling early-stage proof-of-concept in Parkinson's disease. Arvinas's strategy combines internal R&D with strategic partnerships, such as its major collaboration with Pfizer, to advance a deep pipeline and solidify its position as a platform innovator and drug developer.
View full company profileOther Undisclosed Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| TAK-186 | Thermo Fisher Scientific | Phase 1 |
| ODM-209 | Orion Corporation | Phase 1 |
| CEL-301 | Celon Pharma | Preclinical |
| ARV-393 | Arvinas | Phase 1 |
| ARV-806 | Arvinas | Phase 1 |
| ARV-027 | Arvinas | Phase 1 |